Recently stock market analysts have updated their consensus ratings on shares of Axovant Sciences (NYSE:AXON). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/23/2016 – Axovant Sciences had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 23 price target on the stock.

02/03/2016 – Axovant Sciences had its “conviction sell” rating reiterated by analysts at Chardan Capital. They now have a USD 8 price target on the stock.

02/02/2016 – Axovant Sciences had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 35 price target on the stock.

02/02/2016 – Axovant Sciences had its “outperform” rating reiterated by analysts at Robert W. Baird. They now have a USD 29 price target on the stock.

07/15/2015 – JMP Securities began new coverage on Axovant Sciences giving the company a “market outperform” rating. They now have a USD 36 price target on the stock.

07/06/2015 – Evercore ISI began new coverage on Axovant Sciences giving the company a “buy” rating. They now have a USD 29 price target on the stock.

07/06/2015 – Jefferies began new coverage on Axovant Sciences giving the company a “buy” rating. They now have a USD 31 price target on the stock.

07/06/2015 – RBC Capital began new coverage on Axovant Sciences giving the company a “outperform” rating. They now have a USD 40 price target on the stock.

Axovant Sciences has a 50 day moving average of 12.30 and a 200 day moving average of 14.56. The stock’s market capitalization is 1.16B, it has a 52-week low of 8.86 and a 52-week high of 31.17.

The share price of the company (NYSE:AXON) was down -4.26%, with a high of 12.24during the day and the volume of Axovant Sciences shares traded was 194541.

View other investors thoughts on Axovant Sciences with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.